Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

addition to, and not as a substitute for, or as superior to, financial measures prepared in accordance with GAAP. A reconciliation of the Company's non-GAAP adjusted financial measures to the corresponding GAAP financial measures, and an explanation of the Company's use of these non-GAAP adjusted financial measures and of the excluded items, are included in the appendix to this press release. - Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, adjusted to exclude certain non-cash and non-recurring items) was $6.9 million. - Adjusted revenue was $63.5 million. - Adjusted costs of goods sold was $28.4 million. - Adjusted research and development expenses were $5.6 million. - Adjusted selling, general and administrative expenses were $21.2 million. - Adjusted net loss and adjusted net loss per share for the quarter were $4.7 million and $0.06, respectively.

Fourth Quarter Highlights

Proprietary Medical Products. Our Proprietary Medical Products are marketed and sold by our two direct sales groups. We believe certain of these product lines contain technological advantages that have the potential for more substantial revenue growth potential as compared to our overall product portfolio. Our most significant commercial Proprietary Medical Products are our Quill(TM) SRS wound closure product line, Skater(TM) line of drainage catheters, Option(TM) Inferior Vena Cava Filter, HemoStream(TM) chronic d
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... a leading provider of strategic communications services to corporations and organizations ... the United States and Europe ... is returning to the firm,s Washington, D.C. ... than two years of service as Associate Commissioner for the Office ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2
... a leading clinical stage biotechnology company with offices ... proprietary stem cell and tissue engineering based therapies, ... Cooperative Research and Development Agreement (CRADA) with the ... at Fort Sam Houston, Texas. The 3-year CRADA, ...
... PARK, Md., June 6, 2011 CosmosID™, a ... (TAP) incubator developing comprehensive pathogen identification technologies, ... life sciences company category during the 2011 Maryland ... (Logo: http://photos.prnewswire.com/prnh/20101005/MTECHLOGO ) In ...
... June 6, 2011 Celtaxsys, Inc., a private biopharmaceutical company ... sciences industry veteran, H. Daniel Perez, M.D., to its Board ... Dr. Perez has joined the Celtaxsys team," says Dr. Michael ... "He brings more than 25 years of high level pharmaceutical ...
Cached Biology Technology:Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 2Arteriocyte and the U.S. Army Institute of Surgical Research (USAISR) Sign a CRADA to Speed Development of Cellular Therapies for Orthopaedic Trauma 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 2Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 3Mtech TAP Company CosmosID™ Wins Best Life Sciences Company in the Maryland Incubator Company of the Year Awards 4Dr. H. Daniel Perez Joins Celtaxsys Board of Directors 2
(Date:7/10/2014)... 10 July 2014 Amyloid diseases, such as ... spongiform encephalopathies, all share the common trait that ... plaques. Yet in vitro studies have found that ... themselves are very toxic. New evidence using two-dimensional ... structure during the amylin aggregation pathway that may ...
(Date:7/10/2014)... 10,2014 For children and teens living with a ... contribute to decreased quality of life, reports a study ... Behavioral Pediatrics , the official journal of the ... The journal is published by Lippincott Williams & ... . , "Self-competence may function as a protective factor ...
(Date:7/10/2014)... natural-color satellite image was collected by the Moderate Resolution ... 10, 2014. Each hot spot, which appears as a ... on the MODIS instrument recognized temperatures higher than background. ... image, such hot spots are diagnostic for fire. ... little danger coming directly from the fires, although the ...
Breaking Biology News(10 mins):New technology reveals insights into mechanisms underlying amyloid diseases 2For children with pacemakers, 'self-competence' affects quality of life 2
... appointment of Esin Gulari, dean of the College of Engineering ... Science Board (NSB). President George W. Bush nominated Gulari for ... is a tremendous honor for me as a scientist and ... in a unique position to make contributions on a national ...
... 3, 2008 Case Western Reserve University School of Medicine ... The National Children,s Study, the National Institutes of Health,s comprehensive ... children,s health. At a briefing today, NIH ... one of 36 new and existing study centers which would ...
... observance of Nuclear Medicine Week (October 5 to 11) ... today a new fact sheet highlighting recent developments in ... in which breast cancer is diagnosed and treated. ... painless imaging tool for diagnosing and treating breast cancer. ...
Cached Biology News:US Senate confirms Clemson University engineering Dean Esin Gulari to National Science Board 2NIH selects Case Western Reserve University to participate in National Children's Study 2SNM releases new fact sheet on breast cancer and molecular imaging 2
... ESGRO Complete Derivation Kit is ... ES cells from delayed blastocysts in ... Clonal ... Delayed Blastocyst Incubation Medium Trypsin ...
Template and primers for preparation of internal control spots...
Reusble. Uses in conjunction with the Apoptotic Cell Isolation Kit....
ANTI K. AEROGENES...
Biology Products: